Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
FDA's evaluation concluded that the criteria weighed against placement on the list, citing inadequate physicochemical characterization, immunogenicity concerns from impurities and aggregates, lack of clinical effectiveness data for any approved use, and absence of published human exposure data for the proposed subcutaneous and topical routes
The metabolism boost helps people lose pounds if they follow a strict diet
Mixing two peptides
Approach Community research planning Duration 8-16 weeks Review Point Every 4 weeks Notes Common research-planning structure with optional review points
As of June 2026, the FDA's December 2024 Pharmacy Compounding Advisory Committee evaluation concluded that the criteria weighed against placing AOD-9604 (free base) or AOD-9604 acetate on the 503A Bulks List, and AOD-9604 is currently listed as Nominated but Withdrawn from FDA Category 2
US$ 25.12
US$ 23.04
US$ 24.61